Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Puma Biotechnology's enterprise value is $305.8 Mil.
Puma Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $45.0 Mil. Therefore, Puma Biotechnology's EV-to-EBITDA for today is 6.80.
The historical rank and industry rank for Puma Biotechnology's EV-to-EBITDA or its related term are showing as below:
PBYI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -600.56 Med: -5.94 Max: 11.72
Current: 6.8
During the past 13 years, the highest EV-to-EBITDA of Puma Biotechnology was 11.72. The lowest was -600.56. And the median was -5.94.
PBYI's EV-to-EBITDA is ranked better than 59.04% of 415
companies
in the Biotechnology industry
Industry Median: 11.92
vs PBYI: 6.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Puma Biotechnology's PE Ratio (TTM) for today is calculated as:
Puma Biotechnology's share price for today is $7.69.
Puma Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Puma Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Puma Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's EV-to-EBITDA falls into.
Puma Biotechnology's current Enterprise Value is $305.8 Mil.
Puma Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology (PBYI) has a EV-to-EBITDA of 6.80 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Puma Biotechnology. According to the industry distribution chart, Puma Biotechnology ranks #170 out of 415 companies in the Biotechnology industry, placing it in the top 41%.
Is Puma Biotechnology's EV-to-EBITDA too high?
Puma Biotechnology's current EV-to-EBITDA is 6.80. The Biotechnology industry median EV-to-EBITDA is 11.92. Puma Biotechnology's value of 6.80 is 43% below this industry median. Based on the distribution chart, Puma Biotechnology ranks #170 out of 415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's EV-to-EBITDA compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #170 out of 415 companies for EV-to-EBITDA. This puts Puma Biotechnology in the upper half of its industry. The industry median EV-to-EBITDA is 11.92. Puma Biotechnology's value of 6.80 is 43% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.92, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current EV-to-EBITDA of 6.80 is 43% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Puma Biotechnology. For the Biotechnology industry, the median EV-to-EBITDA is 11.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current EV-to-EBITDA is 6.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current EV-to-EBITDA is 6.80 and 43% below the Biotechnology industry median of 11.92. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current EV-to-EBITDA is 6.80 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
EV-to-EBITDA: 6.80
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
Industry Position: 43% below the Biotechnology median (#170 of 415)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
